SG173397A1 - Compositions and methods for the treatment of mucositis - Google Patents

Compositions and methods for the treatment of mucositis Download PDF

Info

Publication number
SG173397A1
SG173397A1 SG2011052230A SG2011052230A SG173397A1 SG 173397 A1 SG173397 A1 SG 173397A1 SG 2011052230 A SG2011052230 A SG 2011052230A SG 2011052230 A SG2011052230 A SG 2011052230A SG 173397 A1 SG173397 A1 SG 173397A1
Authority
SG
Singapore
Prior art keywords
compound
formula
alkyl
compounds
formulae
Prior art date
Application number
SG2011052230A
Other languages
English (en)
Inventor
C Eric Schwartz
Per Gjorstrup
Original Assignee
Resolvyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resolvyx Pharmaceuticals Inc filed Critical Resolvyx Pharmaceuticals Inc
Publication of SG173397A1 publication Critical patent/SG173397A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG2011052230A 2006-07-19 2007-07-19 Compositions and methods for the treatment of mucositis SG173397A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83186606P 2006-07-19 2006-07-19

Publications (1)

Publication Number Publication Date
SG173397A1 true SG173397A1 (en) 2011-08-29

Family

ID=38617335

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011052230A SG173397A1 (en) 2006-07-19 2007-07-19 Compositions and methods for the treatment of mucositis

Country Status (14)

Country Link
US (1) US20100035989A1 (enExample)
EP (1) EP2049099A1 (enExample)
JP (1) JP2009545527A (enExample)
KR (1) KR20090040323A (enExample)
CN (1) CN101528218A (enExample)
AU (1) AU2007275658B2 (enExample)
BR (1) BRPI0714562A2 (enExample)
CA (1) CA2658361C (enExample)
IL (1) IL196465A0 (enExample)
MX (1) MX2009000657A (enExample)
RU (1) RU2009101324A (enExample)
SG (1) SG173397A1 (enExample)
WO (1) WO2008011085A1 (enExample)
ZA (1) ZA200900388B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) * 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
US20090118243A1 (en) * 2007-10-12 2009-05-07 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
JP2011519373A (ja) 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
EP2299997A4 (en) 2008-06-19 2012-01-11 Univ Utah Res Found USE OF NITRATED LIPIDS FOR THE TREATMENT OF SIDE EFFECTS OF TOXIC MEDICAL THERAPIES
US20120122816A1 (en) * 2009-02-05 2012-05-17 Resolvyx Pharmaceuticals, Inc. Compositions and methods for organ preservation
US8853437B2 (en) 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
US9066902B2 (en) 2009-07-31 2015-06-30 University of Pittsburgh—of the Commonwealth System of Higher Education Fatty acids as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US20150018417A1 (en) * 2012-02-03 2015-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acids as anti-inflammatory agents
CN103417471A (zh) * 2012-05-22 2013-12-04 吴升华 一种治疗湿疹等皮肤炎症的脂氧素乳膏
ES2751495T3 (es) 2013-08-19 2020-03-31 Enzychem Lifesciences Corp Composiciones que contienen un compuesto monoacetildiglicérido como un componente activo para prevenir o tratar la artritis reumatoide
DK3097910T3 (da) * 2014-01-24 2020-07-27 Univ Kyoto Antiinflamatorisk middel indeholdende sjælden fedtsyre
TW201609086A (zh) 2014-05-15 2016-03-16 安塞全生命科學公司 白血球減少症和血小板減少症之治療方法
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
MX2018004043A (es) 2015-10-02 2018-11-09 Complexa Inc Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
CN112469413B (zh) 2018-05-25 2024-01-12 伊马拉公司 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
WO2000054761A2 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Regulation of phospholipase d activity
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US7700650B2 (en) * 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
DE60229640D1 (de) * 2001-03-02 2008-12-11 Brigham & Womens Hospital Lipoxin analoge als neue inhibitoren der angiogenese
WO2003048148A2 (en) * 2001-12-03 2003-06-12 Novozymes A/S Statin-like compounds
AU2002365167A1 (en) * 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
EP1528909A4 (en) * 2002-04-01 2006-05-24 Univ Southern California TRI-HYDROXY-POLYUNG-SATURATED EICOSANOIDS
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
ATE382597T1 (de) * 2002-06-17 2008-01-15 Resolvyx Pharmaceuticals Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004014835A2 (en) * 2002-08-12 2004-02-19 Brigham And Women's Hospital Resolvins: biotemplates for therapeutic interventions
US20050113443A1 (en) * 2003-06-01 2005-05-26 Karp Christopher L. Modulation of airway inflammation in patients with cystic fibrosis and related diseases
US20050203184A1 (en) * 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
AU2005306320B2 (en) * 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases

Also Published As

Publication number Publication date
KR20090040323A (ko) 2009-04-23
WO2008011085A1 (en) 2008-01-24
CA2658361A1 (en) 2008-01-24
CA2658361C (en) 2013-04-23
JP2009545527A (ja) 2009-12-24
CN101528218A (zh) 2009-09-09
BRPI0714562A2 (pt) 2013-04-02
IL196465A0 (en) 2009-11-18
RU2009101324A (ru) 2010-07-27
MX2009000657A (es) 2009-05-28
AU2007275658B2 (en) 2011-09-01
AU2007275658A1 (en) 2008-01-24
US20100035989A1 (en) 2010-02-11
ZA200900388B (en) 2010-03-31
EP2049099A1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
SG173397A1 (en) Compositions and methods for the treatment of mucositis
EP2207543A2 (en) Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
AU2008312006B2 (en) Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxyliptin compounds for the treatment of ophthalmic conditions
EP0792163B1 (en) Acne treating-wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
DE60106905T2 (de) Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp
US20080161275A1 (en) Compositions and methods for the treatment of inflammatory disease
AU2015274361A1 (en) Combination therapy with glutaminase inhibitors
KR100424503B1 (ko) 암전이억제제
US11951114B2 (en) Use of thyroid beta-agonists
KR20110028454A (ko) 다발성 골수종 치료법
JP2019524852A (ja) グルタミナーゼ阻害剤を用いる併用療法
RU2468800C2 (ru) Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
WO2008057283A2 (en) Use of resolvins for inhibition of bone loss
CN112370446A (zh) Egcg药物组合物及其制备方法和在卵巢功能保护中的应用
US9403791B1 (en) Coumarin derivatives for cancer therapy
AU2016340017A1 (en) Compositions and methods for the treatment of diseases involving mucin
KR20080038085A (ko) 구강과 위장관 점막염의 악화를 경감하는 방법
EP4301370A1 (en) Combinatory therapy for preventing, inhibiting, treating, or reducing aneurysms
JP5928787B2 (ja) 皮膚線維化抑制剤
AU2014201375A1 (en) Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
HK40007271A (en) Use of thyroid beta-agonists